Ophthalmology Times

Ophthalmology Times Cutting-Edge Advancements
Twitter.com/OphthTimes Posting Policy:
Thank you for liking the official Ophthalmology Times page. We're glad you're here.

We are committed to creating a community that encourages self-expression and mirrors the values of Ophthalmology Times including respect for the rights, dignity, and property of others. We ask all fans to do their part to help us achieve the goal. In doing that, we ask you not to post content that:
-is threatening, abusive, obscene, indecent, or objectionable.
-is deceptive, false, or misleading
-

violates the intellectual property rights of other people
-is illegal
-references a third party website or is self-promoting spam
-is inappropriate, offensive, or hateful
We reserve the right to remove any content or block users that violate our community guidelines, or that we determine are otherwise offensive to our community. All content must also comply with Facebook's policies as well.

Bayer has completed its acquisition of Perfuse Therapeutics—in addition, the company has also entered a drug discovery c...
06/26/2026

Bayer has completed its acquisition of Perfuse Therapeutics—in addition, the company has also entered a drug discovery collaboration with Iambic Therapeutics. The deals signal a dual-track expansion of Bayer's ophthalmology and pharmaceutical research portfolio.

With Perfuse Therapeutics fully integrated into Bayer, the company now holds full rights to PER-001 intravitreal implant, a first-in-class sustained-release small molecule endothelin receptor antagonist in phase II clinical development for glaucoma and diabetic retinopathy (DR).

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.

Memento Medicines, a privately held biotech developing biologic therapies for retinal disease, has launched with a $93 m...
06/25/2026

Memento Medicines, a privately held biotech developing biologic therapies for retinal disease, has launched with a $93 million Series A round co-led by Forbion, RA Capital Management, and Avego BioScience Capital. Alongside the launch, the company secured worldwide rights for MMT-205 through an exclusive license agreement with South Korea–based MabTics http://Co., Ltd. and Curacle http://Co., Ltd.

The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.

Atsena Therapeutics has dosed the first patient in the Phase 3 pivotal cohort of the LIGHTHOUSE trial, advancing ATSN-20...
06/24/2026

Atsena Therapeutics has dosed the first patient in the Phase 3 pivotal cohort of the LIGHTHOUSE trial, advancing ATSN-201 into the registrational stage of development for X-linked retinoschisis (XLRS) and moving the program closer to what would be the first approved therapy for the disease.

Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated. The company is targeting completion of enrollment by the end of the first quarter of 2027, topline results in the first half of 2028, and a Biologics License Application (BLA) filing in the second half of 2028.

Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.

ARPA-H has awarded up to $75.8 million to four research teams through its Ocular Laboratory for Analysis of Biomarkers (...
06/23/2026

ARPA-H has awarded up to $75.8 million to four research teams through its Ocular Laboratory for Analysis of Biomarkers (OCULAB) program, with the goal of developing a closed-loop tear-duct biosensor and drug delivery system capable of continuous, real-time disease monitoring and personalized treatment.

ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.

A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with ...
06/23/2026

A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes—findings from a retrospective single-center study, published in the Journal of Glaucoma, assessing the safety and efficacy of direct selective laser trabeculoplasty (DSLT) in patients with ocular hypertension (OHT) or open angle glaucoma (OAG).

A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.

Nicox has announced that its exclusive licensee in China, Ocumension Therapeutics, received positive pre-submission regu...
06/22/2026

Nicox has announced that its exclusive licensee in China, Ocumension Therapeutics, received positive pre-submission regulatory feedback from the Chinese Center for Drug Evaluation for NCX 470

NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.

Training a computer vision model on a 50:50 blend of synthetic and real eye images produces more reliable segmentation o...
06/20/2026

Training a computer vision model on a 50:50 blend of synthetic and real eye images produces more reliable segmentation of the pupil, iris, and sclera than training on either image type alone, according to a cross-domain validation study published in Cureus.

The investigators, led by Krishna Keshav, a medical student at All India Institute of Medical Sciences, New Delhi, and corresponding author Deepsekhar Das, MD, assistant professor, set out to address one of the persistent bottlenecks in building ophthalmic AI: assembling large, well-annotated, ethically sourced image datasets.

A balanced mix of AI-generated and smartphone-captured images eliminated the domain-specific failures seen with single-source training

Asking multimodal large language models (LLMs) to reason step by step before answering improved both their accuracy and ...
06/19/2026

Asking multimodal large language models (LLMs) to reason step by step before answering improved both their accuracy and the clinical interpretability of their responses on complex ophthalmology questions

Step-by-step prompting boosts multimodal AI accuracy on bilingual ophthalmology vignettes with images—but weak subspecialty and image-reading skills remain.

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant (LBS-008; Belite Bio), an investigational...
06/18/2026

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant (LBS-008; Belite Bio), an investigational once-daily oral therapy for Stargardt disease type 1 (STGD1)—a rare inherited retinal dystrophy for which no approved pharmacologic treatment currently exists.

The filing, initiated in April 2026 and submitted under Breakthrough Therapy Designation (BTD), positions tinlarebant as a potential first-in-class therapy for a condition affecting an estimated 53,000 patients in the United States alone.

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.

The US Food and Drug Administration has accepted for review the Biologics License Application (BLA) for ONS-5010 (LYTENA...
06/17/2026

The US Food and Drug Administration has accepted for review the Biologics License Application (BLA) for ONS-5010 (LYTENAVA) for the treatment of neovascular age-related macular degeneration (nAMD) from Outlook Therapeutics. The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.

The company had submitted the BLA to the FDA at the beginning of June 2026, following a CRL the company had received in December 2025. The journey to FDA approval has been an arduous one for the company, starting in 2022 with the first BLA submission to the FDA. Since then, the company has received 3 CRLs from the organization—with many back-and-forth meetings to determine the path forward.

The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.

Address

25115 Country Club Boulevard
North Olmsted, OH
44070

Telephone

(440) 243-8100

Website

Alerts

Be the first to know and let us send you an email when Ophthalmology Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Ophthalmology Times:

Shortcuts

Share

Category